
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly is expected to see a strong increase in revenue and EPS through 2026 to 2028, with a PT target of $1,230 and an OW rating. This is likely due to their successful acquisition of CNTA and Kelonia Therapeutics, as well as a positive outlook for their current key products in the neuroscience, cardiometabolic, and immunology spaces. The 1Q26 IPR&D charge of $584M may have a slight impact on EPS, but overall, their financials and acquisitions point to a promising future for the company.
Bears say
Eli Lilly is facing significant downside risks, including potential pricing and rebate pressure, slower-than-expected growth of tirzepatide and forglipron, and underperformance of its pipeline products. Recent negative headlines regarding an unadjudicated adverse event in the company's FAERS database raise red flags, further justifying a negative outlook. With 1Q26 revenues and EPS forecasted below consensus, and LLY's 2026, 2027, and 2028 revenues and EPS projected to fall short as well, the company's financials are not supporting a positive outlook for the stock.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares